*XIAOLONG YANG

Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets

Challenge: One of the major challenges for disease treatment is the identification of efficacious drug targets. To overcome the problem, one proposed solution is the use of combined drug therapy that either targets two genes simultaneously or interfere with a single gene with loss-of-function of another one. In both cases this will induce cell synthetic lethality. A synthetic lethal screen … Read More

YVES FRADET

Development of immunotherapy for bladder cancer using IMV’s drug delivery platform

Challenge: Bladder cancer is 5 th in frequency in Canada. Each year, approximately 80,000 people will be diagnosed with bladder cancer and more than 20 % of them will die from the disease. The treatment of advanced bladder cancer has been revolutionized in the recent years by the impressive clinical success of immune checkpoint (IC)-based immunotherapy. Advanced bladder cancer has been shown to … Read More

BORHANE ANNABI

Pre-clinical design of a novel targeted and personalized treatment against Sortilin-positive triple negative breast cancers

Challenge: Triple negative breast cancer (TNBC) accounts for 15 to 20% of diagnosed breast tumors. This type of breast cancer is particularly aggressive and associated with a high risk of recurrence, especially in the first five years after diagnosis. TNBC treatment is limited to chemotherapy that can be combined with surgery and/or radiotherapy. Targeted therapy in not currently a therapeutic … Read More

*DANIEL CHELSKY

Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets

Challenge: Cancer remains a leading cause of death in the developed world. Endocrine tumors derived from hormone-producing cells are particularly problematic. This type of tumor can over-produce hormones, which can induce serious complications. Early and accurate diagnosis is currently very difficult, and treatments of late-stage tumors are ineffective. There is, therefore, an urgent need to improve diagnosis and develop more … Read More

RICHARD MARTEL

A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers

Challenge: Extensive characterization of tumors is central to the development of personalized therapies such as immunotherapy, now considered one of the most promising approaches to cancer treatment. The capability to detect a multitude of biomarkers simultaneously on the same tissue section would provide unprecedented headways in the field of cancer research and particularly on tumor profiling. While allowing a greater … Read More

*RICHARD KREMER

Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs

Challenge: A major challenge in cancer therapy is to stop cancer cells before they metastasize to other tissues, at which point the disease may become resistant to therapeutic intervention. During cancer progression, circulating tumor cells (CTCs) are shed from the primary tumor or its metastatic sites and their number follow closely the progression of the disease. However, CTCs are heterogenous … Read More

CLAIRE DUBOIS

Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance

Challenge: Classical medical Avatar models involve implanting patient tumor samples in immunodeficient mice for subsequent drug testing to tailor the optimal drug or combination of drugs to a given patient. This strategy proves to be an excellent approach for personalized medicine in various cancer indications such as melanoma, lung cancer, and breast cancer. Nevertheless, this model has important limitations, including … Read More

CLAUDE PERREAULT

Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias

Challenge: Acute myeloid and lymphoid leukemias (AML and ALL) are lethal hematologic cancers that affect both children and adults. Despite major progress in the treatment of pediatric AML and ALL, relapse and disease progression in patients with high-risk disease remain common problems. Furthermore, current drugs and radiotherapy treatments are associated with a wide array of long-term side effects. The idea … Read More

ALAIN NEPVEU

Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers

Challenge: Triple-negative breast cancer (TNBC) accounts for 15 to 20 % of all breast cancer patients, but for about 25 % of all breast cancer deaths. There is currently no targeted treatment for TNBC, while only about 30 % of TNBCs are sensitive to conventional therapies. In addition, no more than 50 % of HER2-positive (HER2+) breast cancer patients respond … Read More

MARK BASIK

TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)

Challenge: Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. Even in the early stages it is treated primarily by chemotherapy, often before surgery. The presence of remaining tumor after chemotherapy signals chemoresistance and poor prognosis resulting in the death of 30 to 40 % of patients with triple negative breast cancer within five years of … Read More